Globus Medical INC: directors' dealings · United States · SEC (Form 4)

About Globus Medical INC

Globus Medical Inc. (NYSE: GMED) is a United States-listed medical technology company traded on the NYSE and headquartered in Audubon, Pennsylvania, United States. Founded in 2003, the company has built its business around musculoskeletal solutions, with an especially strong franchise in spine, and a broader presence in orthopedic trauma, joint reconstruction, regenerative biomaterials, and enabling technologies. Its model combines product design, manufacturing, commercialization, and clinical support, giving it a vertically integrated platform that is intended to serve surgeons and hospitals with procedure-based solutions rather than isolated products. ([investors.globusmedical.com](https://investors.globusmedical.com/?utm_source=openai)) From an equity analyst perspective, GMED is positioned in a structurally attractive market. Demand is supported by aging populations, the prevalence of spinal disorders, and the ongoing shift toward more efficient, less invasive procedures. Globus differentiates itself through a sustained innovation culture, a broad procedural portfolio, and a high-touch commercial model that aims to maintain close relationships with surgeons and care teams. The company describes itself as a single operating platform, which helps align research, development, manufacturing, education, and sales around unmet clinical needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000156276225000026/gmed-20241231x10k.htm?utm_source=openai)) The company’s roots are in spine, where it initially established its brand and technical credibility, before expanding into adjacent musculoskeletal categories. In recent years, its strategic profile has become more ambitious through major transactions, most notably the NuVasive acquisition and the completion of the Nevro acquisition in 2025. Management has emphasized that integration remains a core operational priority, alongside a robust new-product pipeline and continued investment in commercial execution. ([investors.globusmedical.com](https://investors.globusmedical.com/news-events/press-releases?utm_source=openai)) Geographically, Globus derives the majority of its business from the United States, while also maintaining international activity through distributors and non-U.S. commercial channels. Recent disclosures point to solid momentum: the company reported 2025 full-year sales of $2.9389 billion, up 16.7%, with fourth-quarter growth driven by the core spine franchise and enabling technologies. In early 2026, management reiterated its focus on above-market growth, product innovation, and disciplined execution as it works through the integration of its acquisitions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1237831/000162828026011124/gmed-ye2025ex991.htm?utm_source=openai)) Overall, Globus Medical can be viewed as a growth-oriented healthcare technology company with a meaningful U.S. spine franchise, expanding procedural breadth, and a strategy centered on innovation, scale, and acquisition integration. ([investors.globusmedical.com](https://www.investors.globusmedical.com/news-events/press-releases?utm_source=openai))